Breast milk-derived synbiotic supplement
Pre-clinical- Indications
- Infant gut dysbiosis
Company intelligence / Profile preview
BoobyBiome has established the world’s first comprehensive database and biobank of the human breast milk microbiome. Their research shows that stored/pumped breastmilk rapidly loses beneficial bacteria compared to direct breastfeeding. The company has developed two main products—a baby bottle accessory that preserves the live bacterial content during storage/feeding, and a synbiotic supplement containing a community of beneficial bacteria plus prebiotics derived from human breastmilk. Early lab studies show their strains can reduce inflammation and support gut integrity in cell models. Clinical trials are planned with the goal of becoming the first infant probiotic with an approved EU health claim.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BoobyBiome.